125 related articles for article (PubMed ID: 23952215)
1. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.
Sarasquete ME; Martínez-López J; Chillón MC; Alcoceba M; Corchete LA; Paiva B; Puig N; Sebastián E; Jiménez C; Mateos MV; Oriol A; Rosiñol L; Palomera L; Teruel AI; González Y; Lahuerta JJ; Bladé J; Gutiérrez NC; Fernández-Redondo E; González M; San Miguel JF; García-Sanz R
Br J Haematol; 2013 Oct; 163(2):223-34. PubMed ID: 23952215
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
[TBL] [Abstract][Full Text] [Related]
3. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Shaughnessy JD; Haessler J; van Rhee F; Anaissie E; Pineda-Roman M; Cottler-Fox M; Hollmig K; Zangari M; Mohiuddin A; Alsayed Y; Grazziutti M; Epstein J; Crowley J; Barlogie B
Br J Haematol; 2007 Jun; 137(6):530-6. PubMed ID: 17489983
[TBL] [Abstract][Full Text] [Related]
4. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
5. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.
Papanikolaou X; Alapat D; Rosenthal A; Stein C; Epstein J; Owens R; Yaccoby S; Johnson S; Bailey C; Heuck C; Tian E; Joiner A; van Rhee F; Khan R; Zangari M; Jethava Y; Waheed S; Davies F; Morgan G; Barlogie B
Leukemia; 2015 Aug; 29(8):1713-20. PubMed ID: 25753926
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
7. Low-risk identification in multiple myeloma using a new 14-gene model.
Chen T; Berno T; Zangari M
Eur J Haematol; 2012 Jul; 89(1):28-36. PubMed ID: 22620863
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
9. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR.
Kaiser MF; Walker BA; Hockley SL; Begum DB; Wardell CP; Gonzalez D; Ross FM; Davies FE; Morgan GJ
Leukemia; 2013 Aug; 27(8):1754-7. PubMed ID: 23318961
[No Abstract] [Full Text] [Related]
10. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
[TBL] [Abstract][Full Text] [Related]
11. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
12. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
13. Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma.
Filipits M; Pohl G; Stranzl T; Kaufmann H; Ackermann J; Gisslinger H; Greinix H; Chott A; Drach J
Clin Cancer Res; 2003 Feb; 9(2):820-6. PubMed ID: 12576455
[TBL] [Abstract][Full Text] [Related]
14. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling and multiple myeloma.
Shaughnessy J; Zhan F; Barlogie B; Stewart AK
Best Pract Res Clin Haematol; 2005; 18(4):537-52. PubMed ID: 16026736
[TBL] [Abstract][Full Text] [Related]
16. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
Hermansen NE; Borup R; Andersen MK; Vangsted AJ; Clausen NT; Kristensen DL; Nielsen FC; Gimsing P
Int J Lab Hematol; 2016 Jun; 38(3):298-307. PubMed ID: 27027250
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling defines a high-risk entity of multiple myeloma.
Zhan FH; Barlogie B; John D S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):191-203. PubMed ID: 17478923
[TBL] [Abstract][Full Text] [Related]
18. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.
Decaux O; Lodé L; Magrangeas F; Charbonnel C; Gouraud W; Jézéquel P; Attal M; Harousseau JL; Moreau P; Bataille R; Campion L; Avet-Loiseau H; Minvielle S;
J Clin Oncol; 2008 Oct; 26(29):4798-805. PubMed ID: 18591550
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.
Atamaniuk J; Gleiss A; Porpaczy E; Kainz B; Grunt TW; Raderer M; Hilgarth B; Drach J; Ludwig H; Gisslinger H; Jaeger U; Gaiger A
Eur J Clin Invest; 2012 Sep; 42(9):953-60. PubMed ID: 22591013
[TBL] [Abstract][Full Text] [Related]
20. [Genetic tools for risk-stratification in multiple myeloma].
Braggio E; Albarracín Garramuño F
Medicina (B Aires); 2013; 73(4):369-75. PubMed ID: 23924539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
